Office of Regulatory Support, Clinical and Translational Science Institute, University of Rochester Medical Center, New York, USA.
Acad Med. 2012 Mar;87(3):279-84. doi: 10.1097/ACM.0b013e318244838a.
Prior to human clinical trials, nonclinical safety and toxicology studies are required to demonstrate that a new product appears safe for human testing; these nonclinical studies are governed by good laboratory practice (GLP) regulations. As academic health centers (AHCs) embrace the charge to increase the translation of basic science research into clinical discoveries, researchers at these institutions increasingly will be conducting GLP-regulated nonclinical studies. Because the consequences for noncompliance are severe and many AHC researchers are unfamiliar with Food and Drug Administration regulations, the authors describe the regulatory requirements for conducting GLP research, including the strict documentation requirements, the necessary personnel training, the importance of study monitoring, and the critical role that compliance oversight plays in the process. They then explain the process that AHCs interested in conducting GLP studies should take before the start of their research program, including conducting a needs assessment and a gap analysis and selecting a model for GLP compliance. Finally, the authors identify and analyze several critical barriers to developing and implementing a GLP-compliant infrastructure at an AHC. Despite these challenges, the capacity to perform such research will help AHCs to build and maintain competitive research programs and to facilitate the successful translation of faculty-initiated research from nonclinical studies to first-in-human clinical trials.
在进行人体临床试验之前,需要进行非临床安全性和毒理学研究,以证明新产品对人体测试是安全的;这些非临床研究受良好实验室规范 (GLP) 法规的约束。随着学术健康中心 (AHC) 承担增加基础科学研究向临床发现转化的任务,这些机构的研究人员将越来越多地进行 GLP 监管的非临床研究。由于不合规的后果严重,而且许多 AHC 研究人员不熟悉食品和药物管理局的规定,作者描述了进行 GLP 研究的监管要求,包括严格的文件要求、必要的人员培训、研究监测的重要性以及合规监督在该过程中发挥的关键作用。然后,他们解释了有兴趣开展 GLP 研究的 AHC 在开始研究计划之前应采取的步骤,包括进行需求评估和差距分析,并选择 GLP 合规模型。最后,作者确定并分析了在 AHC 中开发和实施符合 GLP 的基础设施的几个关键障碍。尽管存在这些挑战,但开展此类研究的能力将有助于 AHC 建立和维持有竞争力的研究计划,并促进从非临床研究到人体首次临床试验的成功转化。